Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate

Nuclear Medicine and Biology

Volumn 29, Issue 1, 2002, Pages 1-11

  Vaidyanathan, Ganesan ^a   Affleck, Donna J ^a   Bigner, Darell D ^a   Zalutsky, Michael R ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Box 3808 ^*  (United States)

Author keywords

Glioma; Iodine 131; Monoclonal antibody; Radioimmunotherapy; Radioiodination

Indexed keywords

4 GUANIDOMETHYL 3 IODOBENZOIC ACID I 131; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IODINE 125; IODINE 131; IODOBENZOIC ACID DERIVATIVE; IODONICOTINIC ACID I 125; MONOCLONAL ANTIBODY L8A4 I 125; MONOCLONAL ANTIBODY L8A4 I 131; N SUCCINIMIDYL 3 IODO 5 PYRIDINECARBOXYLATE I 125; N SUCCINIMIDYL 4 [N1,N2 BIS(TERT BUTYLOXYCARBONYL)GUANIDINOMETHYL] 3 IODOBENZOIC ACID I 131; N SUCCINIMIDYL 4 GUANIDINOMETHYL 3 IODOBENZOATE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG STABILITY; DRUG UPTAKE; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; PROTEIN VARIANT; RADIOACTIVITY; RADIOIODINATION; TARGET ORGAN; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; GLIOMA; HUMANS; MICE; MICE, INBRED BALB C; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; UREA; XANTHINE; XANTHINES;

EID: 0036151245     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(01)00277-3     Document Type: Article

References (33)

1. Dosimetry and dose-response relationships in newly diagnosed patients treated with iodine-131-labeled anti-tenacin monoclonal antibody therapy
2. Improving the tumor retention of radioiodinated antibody: Aryl carbohydrate adducts
3. Iodine-131-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results
4. 131I-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas
5. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails
6. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody
7. N-succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates: A new class of reagents for protein radioiodination
8. Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate
9. The synthesis of hippurate from benzoate and glycine by rat liver mitochondria
10. Labeling of monoclonal antibodies with diethylene-triaminepentaacetic acid-appended radioiodinated peptides containing D-amino acids
11. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts
12. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess
13. Neurooncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy
14. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
15. Relationships between tumor size and curability for uniformly targeted radiotherapy with beta-emitting radionuclides
16. Neoplasms of the central nervous system
17. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells
18. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: Use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts
19. Radioiodinated of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate
20. Improved targeting of an anti-EGFRvIII monoclonal antibody in tumor xenografts after labeling using N-succinimdyl 5-iodo-3-pyridinecarboxylate
21. 131I: Comparison of the results obtained in recurrent and newly diagnosed tumors
22. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma-phase I and II study
23. 131I-labeled monoclonal antibodies? Some dosimetric considerations, Recent Results
24. Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma
25. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors
26. 131I]iodobenzoate
27. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas
28. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRVIII
29. Structural alterations of the epidermal growth factor receptor gene in human gliomas
30. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies
31. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl) benzoate
32. Astatine-211-labeled radiotherapeutics: An emerging approach to targeted alpha particle therapy